<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334551</url>
  </required_header>
  <id_info>
    <org_study_id>Doravirine and HIV VT#59184</org_study_id>
    <nct_id>NCT04334551</nct_id>
  </id_info>
  <brief_title>HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance</brief_title>
  <official_title>A Pilot, Prospective, Non-randomized Study to Evaluate the Safety and Efficacy of Switches From Etravirine to Doravirine, in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique du Quartier Latin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Frosst Canada Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinique du Quartier Latin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, open, prospective, non-randomized study to evaluate the safety and efficacy
      of switches from etravirine to doravirine, in experienced patients with multiple class
      resistance including NNRTI resistance. The other ARV medication (protease inhibitor, entry
      inhibitor and integrase inhibitor) that some patients receive, in addition to the NRTI and
      NNRTI, will not be changed.

      The study will be performed only on two sites
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study will be of 120 weeks: 24 for recruitment and 96 weeks of follow-up.
      The reasons for the study duration of 2 years is that, up to now, doravirine has not been
      studied in 2 or 3 classes multi-drug-resistance (MDR) and thus, demonstration of durability
      of effect over a prolonged period of time is as important as the short-term efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A pilot, prospective, non-randomized study to evaluate the safety and efficacy of switches from etravirine to doravirine, in experienced patients with multiple class resistance including NNRTI resistance</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects who maintain virologic control .</measure>
    <time_frame>24 weeks</time_frame>
    <description>Virologic control is defined by measurement of HIV-1 RNA &lt; 50 copies/mL.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>switch from etravirine to doravirine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>switches to doravirine,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doravirine</intervention_name>
    <description>switches from etravirine to doravirine, in experienced HIV patients</description>
    <arm_group_label>switch from etravirine to doravirine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Adult (18 Y.O. or more) women and men infected with HIV.

          -  Treated with etravirine and at least 2 others ARV in the other classes: NRTI, PI,
             INSTI, EI, for at least 12 months.

          -  Virologically controlled (HIV-1 RNA &lt; 50 copies/mL) since at least 6 months. Blips
             (HIV-ARN ≥ 50 copies/mL, one time, with return to virologic control at the next visit)
             are allowed.

          -  Presence of at least one major NNRTI mutation.

          -  No limitation on the number of previous regimens.

          -  HCV and HBV-infected patients are allowed

        Exclusion Criteria:

        High level of resistance to doravirine according to historical resistance tests.

          -  Level of resistance to doravirine superior to that of etravirine

          -  Opportunistic or serious active infection or disease

          -  Active and untreated malignancy.

          -  Current psychiatric or neurocognitive condition judged by the Investigator to
             potentially interfere with study visits and procedures

          -  Pregnancy.

          -  Active treatment for hepatitis C is forbidden at entry but will be allowed after 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ioannis vertzagias</last_name>
    <phone>5142853401</phone>
    <email>ivertzagias@cmql.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>benoit trottier, MD</last_name>
    <phone>5142853401</phone>
    <email>bentrotte@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Du Quartier Latin</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Ioannis vertzagias</last_name>
      <phone>5142853401</phone>
      <email>ivertzagias@cmql.ca</email>
    </contact>
    <investigator>
      <last_name>Benoit Trottier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Martinique</name>
      <address>
        <city>Fort-de-France</city>
        <state>Fort De France</state>
        <zip>CS 90632</zip>
        <country>Martinique</country>
      </address>
    </facility>
    <contact>
      <last_name>André Cabie</last_name>
      <phone>0596 55 23 73</phone>
      <email>Andre.CABIE@chu-martinique.fr</email>
    </contact>
    <investigator>
      <last_name>Lise Cuzin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Martinique</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinique du Quartier Latin</investigator_affiliation>
    <investigator_full_name>Benoit Trottier</investigator_full_name>
    <investigator_title>Dr Benoit Trottier Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

